EZH2 and prostate cancer: The work of Shah et al. (2017) showed that loss of the repressive signals of both AR binding and EZH2-mediated methylation of a tissue-specific enhancer at the GR locus lead to upregulation of GR and drug resistance in prostate cancer cells.